BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28600702)

  • 1. Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature.
    Lertxundi U; Marquínez AC; Domingo-Echaburu S; Solinís MÁ; Calvo B; Del Pozo-Rodríguez A; García M; Aguirre C; Isla A
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1159-1164. PubMed ID: 28600702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
    Garcia-Ruiz PJ; Martinez Castrillo JC; Alonso-Canovas A; Herranz Barcenas A; Vela L; Sanchez Alonso P; Mata M; Olmedilla Gonzalez N; Mahillo Fernandez I
    J Neurol Neurosurg Psychiatry; 2014 Aug; 85(8):840-4. PubMed ID: 24434037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older.
    Fasano A; Guidubaldi A; De Nigris F; Bentivoglio AR
    J Am Geriatr Soc; 2011 Dec; 59(12):2386-7. PubMed ID: 22188090
    [No Abstract]   [Full Text] [Related]  

  • 6. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
    Katunina EA; Titova NV; Bezdolny YN; Shykkerimov RK; Gasanov MG; Burd SG; Lebedeva AV; Boiko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(5):34-40. PubMed ID: 26356158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 12. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
    Woitalla D; Dunac A; Safavi A; Ceravolo MG; Gomez Esteban JC; Pavese N; Asgharnejad M; Joeres L; Schuller JC; Chaudhuri KR
    Expert Opin Pharmacother; 2018 Jun; 19(9):937-945. PubMed ID: 29916262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hiccups associated with non-ergoline dopamine agonists in Parkinson's disease.
    Coletti Moja M
    Mov Disord; 2010 Jul; 25(9):1292. PubMed ID: 20310014
    [No Abstract]   [Full Text] [Related]  

  • 18. [Rotigotine in the treatment of Parkinson's disease. A study on a sample of 150 patients].
    Ruiz-Huete C; Bermejo PE; Terrón C; Anciones B
    Rev Neurol; 2008 Mar 1-15; 46(5):257-60. PubMed ID: 18351563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hiccups and dopamine.
    Stegmeier-Petroianu A; Petroianu GA
    Am J Health Syst Pharm; 2008 Nov; 65(22):2092-4. PubMed ID: 18997134
    [No Abstract]   [Full Text] [Related]  

  • 20. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
    Ceballos-Baumann A; Häck HJ
    Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.